| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Human Genetics, University of Michigan, AnnArbor,Michigan 48109–0618
The search for new anticopper drugs for Wilson's disease is culminating in two excellent new drugs: zinc for maintenance therapy and tetrathiomolybdate (TM) for initial therapy. Both are effective and nontoxic. TM is a very potent, fast-acting new anticopper drug and its properties may be useful well beyond Wilson's disease. Angiogenesis (new blood vessel growth) is required for tumor growth, and a sufficient level of copper appears to be required for angiogenesis. We hypothesize that there is a ``window'' to which the copper level can be reduced that inhibits angiogenesis in tumors, but does not interfere with vital cellular functions of copper. Using TM therapy, this approach has worked to slow or stabilize tumor growth in several animal tumor models, and preliminary results are also very encouraging in human patients with a variety of advanced and metastatic malignancies. A hypothesis is advanced that copper availability has played a fundamental role in growth regulation throughout evolution and that is the reason that so many angiogenic promoters appear to be dependent upon copper levels.
Key Words: copper • angiogenesis • cancer • tetrathiomolybdate • zinc
This article has been cited by other articles:
|
|
 |
|
  H. Kim, H.-Y. Son, S. M. Bailey, and J. Lee Deletion of hepatic Ctr1 reveals its function in copper acquisition and compensatory mechanisms for copper homeostasis Am J Physiol Gastrointest Liver Physiol, February 1, 2009; 296(2): G356 - G364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Lowndes, A. Adams, A. Timms, N. Fisher, J. Smythe, S. M. Watt, S. Joel, F. Donate, C. Hayward, S. Reich, et al. Phase I Study of Copper-Binding Agent ATN-224 in Patients with Advanced Solid Tumors Clin. Cancer Res., November 15, 2008; 14(22): 7526 - 7534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Du, G. Filiz, A. Caragounis, P. J. Crouch, and A. R. White Clioquinol Promotes Cancer Cell Toxicity through Tumor Necrosis Factor {alpha} Release from Macrophages J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 360 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cuzzocrea, T. Genovese, M. Failla, G. Vecchio, M. Fruciano, E. Mazzon, R. Di Paola, C. Muia, C. La Rosa, N. Crimi, et al. Protective effect of orally administered carnosine on bleomycin-induced lung injury Am J Physiol Lung Cell Mol Physiol, May 1, 2007; 292(5): L1095 - L1104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Hassouneh, M. Islam, T. Nagel, Q. Pan, S. D. Merajver, and T. N. Teknos Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer Mol. Cancer Ther., March 1, 2007; 6(3): 1039 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Chen, Q. C. Cui, H. Yang, R. A. Barrea, F. H. Sarkar, S. Sheng, B. Yan, G. P. V. Reddy, and Q. P. Dou Clioquinol, a Therapeutic Agent for Alzheimer's Disease, Has Proteasome-Inhibitory, Androgen Receptor-Suppressing, Apoptosis-Inducing, and Antitumor Activities in Human Prostate Cancer Cells and Xenografts Cancer Res., February 15, 2007; 67(4): 1636 - 1644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. McCarty and K. I. Block Preadministration of High-Dose Salicylates, Suppressors of NF-{kappa}B Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation Therapy Integr Cancer Ther, September 1, 2006; 5(3): 252 - 268. [Abstract] [PDF]
|
|
|
|
 |
|
 M. K. Khan, F. Mamou, M. J. Schipper, K. S. May, A. Kwitny, A. Warnat, B. Bolton, B. M. Nair, M. S. T. Kariapper, M. Miller, et al. Combination tetrathiomolybdate and radiation therapy in a mouse model of head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg, March 1, 2006; 132(3): 333 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-Q. Ding, B. Liu, J. L. Vaught, H. Yamauchi, and S. E. Lind Anticancer Activity of the Antibiotic Clioquinol Cancer Res., April 15, 2005; 65(8): 3389 - 3395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. K. Askari, R. Dick, M. Mao, and G. J. Brewer Tetrathiomolybdate Therapy Protects Against Concanavalin A and Carbon Tetrachloride Hepatic Damage in Mice Experimental Biology and Medicine, September 1, 2004; 229(8): 857 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Prudovsky, A. Mandinova, R. Soldi, C. Bagala, I. Graziani, M. Landriscina, F. Tarantini, M. Duarte, S. Bellum, H. Doherty, et al. The non-classical export routes: FGF1 and IL-1{alpha} point the way J. Cell Sci., December 15, 2003; 116(24): 4871 - 4881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Brewer and S. D. Merajver Cancer Therapy With Tetrathiomolybdate: Antiangiogenesis by Lowering Body Copper--A Review Integr Cancer Ther, December 1, 2002; 1(4): 327 - 337. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
